Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study
To the Editor: Systemic corticosteroids and tumor necrosis factor-alpha (TNF-) antagonists are first-line therapies for neutrophilic dermatoses (NDs) associated with Crohn's disease (CD), the most frequent being pyoderma gangrenosum (PG). 1 Ustekinumab, a monoclonal antibody directed against the interleukin 12/interleukin 23 p40 subunit, was recently approved for use in CD. 2 This multicenter retrospective study conducted in 9 French hospitals between January 2013 and July 2017 assessed the efficacy of ustekinumab in CD-associated ND. Consecutive patients referred for active CD-associated ND and treated with ustekinumab following ND onset were included. Diagnosis of ND was based on previously published diagnostic criteria for NDs 3 and confirmed by skin biopsy. The efficacy of ustekinumab was assessed at week 16 after initiation: efficacy in relation to ND was evaluated by determining whether it resulted in a complete, partial (a [50% reduction in symptoms), or no response, and efficacy in relation to CD was evaluated by using the Harvey-Bradshaw index.
The study included 7 patients from among the 320 of 8298 patients with CD who received ustekinumab; the 7 patients included 5 women, 4 patients with PG, 2 with amicrobial pustulosis of the folds (APF), and 1 with chronic recurring Sweet syndrome (Table I ). The result of microbiologic skin sampling was negative except in the case of patient 6, who had staphylococcal superinfection, as is frequently reported in APF. 3 The median ages at onset of ND and CD were 28 years (range, 6-43] and 22 years (range, 13-38), respectively. The median durations of ND and CD at initiation of ustekinumab therapy were 4 and 8 years, respectively. Of the 7 patients studied, 4 had active CD at initiation of ustekinumab therapy; 6 of the 7 patients had previously received TNFantagonists that were discontinued because of side effects or inefficacy. A history of lupus erythematosus contraindicated in patient 5. Patients received ustekinumab, 90 mg every 8 weeks subcutaneously, with slightly varying induction protocols for both CD and ND treatment (Table I) .
At week 16, although most NDs were refractory to multiple therapies and ustekinumab was used as the third to eighth line of treatment, ustekinumab induced remission of ND in 6 of 7 cases (86%) ( Table I) : complete response in 4 of 7 cases (57%), partial response in 2 of 7 cases (29%), and no response in 1 case ( patient 7 with refractory recurring Sweet syndrome). At week 16, the CD of 4 patients who had active CD on day 0 was in complete remission, 2 patients had stable CD with prolonged remission, and 1 patient had a worsening of CD activity that had previously been controlled by adalimumab. No serious side effects were reported. The median follow-up time was 36 months. One patient with ND eventually relapsed ( patient 2). A literature review yielded 12 additional cases of ND that had been successfully treated with ustekinumab; of the total of 13 patients (11 with PG and 2 with APF), 9 (69%) were complete responders 4,5 and 3 (23%) were partial responders (Table II [6] [7] [8] [9] [10] [11] [12] [13] ). The limitations of our study are linked to its retrospective nature. Open labeled or randomized studies are needed to confirm these results. Associated immunosuppressants were sometimes required because of the severity of the ND (in patients 3 and 5); however, ustekinumab allowed tapering and/or discontinuation of the associated therapies.
Ustekinumab may control both ND and CD. It should therefore be considered as alternative therapy for refractory ND in cases of resistance, intolerance, or contraindication to corticosteroids or TNF-antagonists. Rigorous screening for atherosclerosis has therefore been proposed for these patients, 2 and there is a need for a noninvasive, simple, and widely available technique for this purpose. High-resolution ultrasonic arterial scanning provides information on arterial atherosclerotic plaques and meets the aforementioned criteria. 3 Carotid intima-media thickness was initially used as a biomarker of
